Mark E Cooper Selected Research

Diabetic Nephropathies (Diabetic Nephropathy)

1/2022	Adverse renal effects of NLRP3 inflammasome inhibition by MCC950 in an interventional model of diabetic kidney disease.
1/2022	Independent of Renox, NOX5 Promotes Renal Inflammation and Fibrosis in Diabetes by Activating ROS-Sensitive Pathways.
10/2021	Association between serum uric acid and renal outcome in patients with biopsy-confirmed diabetic nephropathy.
4/2021	Targeting Methylglyoxal in Diabetic Kidney Disease Using the Mitochondria-Targeted Compound MitoGamide.
2/2021	Comparison of Circulating Biomarkers in Predicting Diabetic Kidney Disease Progression With Autoantibodies to Erythropoietin Receptor.
1/2021	Targeted deletion of nicotinamide adenine dinucleotide phosphate oxidase 4 from proximal tubules is dispensable for diabetic kidney disease development.
4/2020	DIABETIC RETINOPATHY, CLASSIFIED USING THE LESION-AWARE DEEP LEARNING SYSTEM, PREDICTS DIABETIC END-STAGE RENAL DISEASE IN CHINESE PATIENTS.
3/2020	Glucose and Blood Pressure-Dependent Pathways-The Progression of Diabetic Kidney Disease.
1/2020	Delineating a role for the mitochondrial permeability transition pore in diabetic kidney disease by targeting cyclophilin D.
1/2020	A physician-initiated double-blind, randomised, placebo-controlled, phase 2 study evaluating the efficacy and safety of inhibition of NADPH oxidase with the first-in-class Nox-1/4 inhibitor, GKT137831, in adults with type 1 diabetes and persistently elevated urinary albumin excretion: Protocol and statistical considerations.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Mark E Cooper Research Topics

Disease

91	Diabetic Nephropathies (Diabetic Nephropathy) 01/2022 - 10/2001
72	Type 2 Diabetes Mellitus (MODY) 10/2021 - 04/2002
53	Albuminuria 04/2021 - 03/2002
36	Inflammation (Inflammations) 01/2022 - 12/2004
33	Atherosclerosis 01/2021 - 07/2002
27	Fibrosis (Cirrhosis) 01/2022 - 06/2002
24	Diabetes Complications 01/2022 - 09/2002
24	Chronic Kidney Failure (Chronic Renal Failure) 12/2021 - 04/2004
22	Hyperglycemia 11/2020 - 07/2003
20	Cardiovascular Diseases (Cardiovascular Disease) 01/2021 - 03/2005
17	Hypertension (High Blood Pressure) 03/2020 - 01/2002
16	Proteinuria 09/2021 - 01/2002
16	Kidney Diseases (Kidney Disease) 02/2021 - 07/2006
15	Vascular Diseases (Vascular Disease) 12/2020 - 01/2004
14	Chronic Renal Insufficiency 02/2021 - 03/2005
13	Diabetes Mellitus 11/2021 - 03/2002
11	Heart Failure 02/2021 - 08/2004
9	Anemia 01/2019 - 09/2004
9	Insulin Resistance 06/2016 - 11/2004
9	Hypertrophy 03/2015 - 03/2002
8	Myocardial Infarction 01/2020 - 04/2007
8	Stroke (Strokes) 01/2020 - 04/2007
8	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/2020 - 08/2005
5	Obesity 11/2021 - 08/2005
5	Body Weight (Weight, Body) 01/2020 - 07/2013
4	Diabetic Retinopathy (Retinopathy, Diabetic) 04/2020 - 02/2004
4	Mitochondrial Diseases (Mitochondrial Disease) 10/2016 - 02/2012
4	Cardiomegaly (Heart Hypertrophy) 08/2008 - 04/2003
3	Hyperlipidemias (Hyperlipidemia) 01/2020 - 11/2005

Drug/Important Bio-Agent (IBA)

38	Advanced Glycation End ProductsIBA 01/2020 - 10/2001
28	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 06/2002
28	CreatinineIBA 01/2021 - 08/2003
25	Angiotensin IIIBA 01/2018 - 06/2002
24	Proteins (Proteins, Gene)FDA Link 01/2021 - 05/2002
22	Apolipoproteins E (ApoE)IBA 01/2021 - 07/2004
19	AlbuminsIBA 06/2021 - 04/2002
17	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2022 - 02/2008
16	ApolipoproteinsIBA 01/2020 - 07/2002
16	Losartan (Cozaar)FDA LinkGeneric 08/2014 - 04/2002
14	CollagenIBA 01/2022 - 10/2001
14	Streptozocin (Streptozotocin)FDA Link 01/2022 - 03/2002
14	NADPH Oxidases (NAD(P)H oxidase)IBA 01/2020 - 02/2008
13	LinagliptinIBA 09/2021 - 11/2013
13	Hemoglobins (Hemoglobin)IBA 06/2021 - 06/2004
13	Receptor for Advanced Glycation End ProductsIBA 11/2020 - 08/2005
13	AntioxidantsIBA 02/2017 - 03/2007
12	perindopril drug combination indapamideIBA 12/2020 - 10/2014
12	Gliclazide (Diamicron)IBA 12/2020 - 10/2014
11	LipidsIBA 11/2021 - 12/2005
10	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 04/2020 - 05/2002
9	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 01/2019 - 01/2002
9	alagebriumIBA 08/2012 - 04/2003
8	Biomarkers (Surrogate Marker)IBA 02/2021 - 01/2011
8	Protein Isoforms (Isoforms)IBA 01/2021 - 11/2004
8	CytokinesIBA 01/2020 - 10/2001
8	AngiotensinsIBA 01/2019 - 03/2003
8	Darbepoetin alfa (Aranesp)FDA Link 01/2019 - 03/2005
8	Insulin (Novolin)FDA Link 08/2015 - 03/2005
7	CholesterolIBA 11/2020 - 06/2004
7	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2020 - 10/2001
7	Perindopril FDA LinkGeneric 01/2019 - 03/2002
7	EnzymesIBA 02/2017 - 03/2003
7	Antihypertensive Agents (Antihypertensives)IBA 01/2010 - 01/2002
6	SodiumIBA 02/2018 - 04/2002
6	MicroRNAs (MicroRNA)IBA 01/2017 - 01/2011
6	Superoxides (Superoxide)IBA 02/2016 - 08/2008
6	Messenger RNA (mRNA)IBA 02/2016 - 05/2002
6	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA 01/2010 - 07/2002
5	empagliflozinIBA 12/2020 - 01/2016
5	Pharmaceutical PreparationsIBA 12/2020 - 08/2004
5	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 11/2020 - 09/2010
5	Fibronectins (Fibronectin)IBA 01/2019 - 12/2002
5	Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA 01/2019 - 07/2009
5	Transforming Growth Factors (Transforming Growth Factor)IBA 01/2019 - 01/2011
5	nephrinIBA 02/2016 - 05/2002
5	Angiotensin Receptor AntagonistsIBA 09/2015 - 01/2002
4	Pyruvaldehyde (Methylglyoxal)IBA 04/2021 - 01/2011
4	Sodium-Glucose Transport ProteinsIBA 02/2021 - 01/2016
4	Blood Glucose (Blood Sugar)IBA 01/2021 - 09/2008
4	setanaxibIBA 01/2020 - 05/2013
4	AutoantigensIBA 01/2019 - 09/2010
4	Extracellular Matrix ProteinsIBA 01/2019 - 09/2004
4	LigandsIBA 01/2019 - 08/2010
4	Peptides (Polypeptides)IBA 01/2019 - 03/2003
4	Protein Kinase CIBA 01/2019 - 11/2004
4	Vascular Cell Adhesion Molecule-1 (Vascular Cell Adhesion Molecule 1)IBA 09/2014 - 07/2002
4	Irbesartan FDA LinkGeneric 08/2014 - 08/2002
4	Biological ProductsIBA 01/2014 - 09/2002
4	Ramipril (Altace)FDA LinkGeneric 01/2014 - 06/2003
4	Valsartan (Vals)FDA Link 06/2010 - 07/2002
4	Amlodipine (Norvasc)FDA LinkGeneric 09/2004 - 01/2003
3	Fatty Acids (Saturated Fatty Acids)IBA 11/2021 - 11/2004
3	omega-Chloroacetophenone (Mace)IBA 01/2021 - 01/2020
3	LipoxinsIBA 01/2021 - 01/2018
3	Oxygen (Dioxygen)IBA 01/2020 - 09/2003
3	Dipeptidyl-Peptidase IV InhibitorsIBA 01/2019 - 09/2015
3	HematinicsIBA 01/2019 - 07/2009
3	Indapamide FDA LinkGeneric 01/2019 - 10/2012

Therapy/Procedure

40	Therapeutics 10/2021 - 01/2002
12	Glycemic Control 03/2020 - 03/2002